liothyronine sodium | 55-06-1

• 物质功能分类: 原料药 - 激素及调节内分泌功能类药 - 甲状腺激素及抗甲状腺药
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: liothyronine sodium
• 英文别名: sodium;4-[4-[(2S)-2-amino-2-carboxyethyl]-2,6-diiodophenoxy]-2-iodophenolate
• CAS: 55-06-1
• 化学式: C₁₅H₁₁I₃NO₄*Na
• 分子量: 672.96
• InChiKey: SBXXSUDPJJJJLC-YDALLXLXSA-M

物化性质

• 熔点：
  205 °C (dec.)(lit.)
• 比旋光度：
  20 º (c=2,alcohol/1.2N HCl)
• 溶解度：
  MNH4OH甲醇溶液：125 g/5mL，澄清，黄棕色
• 碰撞截面：
  205.2 Ų [M+H]+ [CCS Type: TW, Method: calibrated with polyalanine and drug standards]

计算性质

• 辛醇/水分配系数(LogP)：
  -0.38
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  95.6
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S22,S24/25
• 危险类别码：
  R20/21/22
• WGK Germany：
  3
• 海关编码：
  2922509090
• 危险品运输编号：
  NONH for all modes of transport
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  本品应密封存于0℃以下干燥、避光的环境中保存。

SDS

Name:	3 3 5- Triiodo-L-Thyronine Sodium Salt 95% Material Safety Data Sheet
Synonym:	Liothyronine Sodium
CAS:	55-06-1

Section 1 - Chemical Product MSDS Name:3 3 5- Triiodo-L-Thyronine Sodium Salt 95% Material Safety Data Sheet
Synonym:Liothyronine Sodium

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
55-06-1	3,3',5- Triiodo-L-Thyronine, Sodium Sa	95%	200-223-5

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Hygroscopic (absorbs moisture from the air).The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Runoff from fire control or dilution water may cause pollution.
Extinguishing Media:
In case of fire, use water, dry chemical, chemical foam, or alcohol-resistant foam. Use agent most appropriate to extinguish fire.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Keep container closed when not in use. Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances. Hormones and antibiotics room. Store protected from moisture.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 55-06-1: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to minimize contact with skin.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: beige
Odor: None reported.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 205 deg C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C15H11I3NO4Na
Molecular Weight: 672.96

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat, strong oxidants, exposure to moist air or water.
Incompatibilities with Other Materials:
Moisture, oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, irritating and toxic fumes and gases, carbon dioxide, nitrogen, hydrogen iodide.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 55-06-1: YP2836500 LD50/LC50:
Not available.
Carcinogenicity:
3,3',5- Triiodo-L-Thyronine, Sodium Salt - Not listed by ACGIH, IARC, or NTP.
Other:
See actual entry in RTECS for complete information.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 55-06-1: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 55-06-1 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 55-06-1 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

碘塞罗宁钠简介

碘塞罗宁钠为白色或类白色的粉末状物，是一种人工合成的三碘甲状腺原氨酸钠。其作用与甲状腺素相似，可作为内源性甲状腺激素的替代物。

药理作用

本品是人工合成制剂，药理作用类似于甲状腺素，但药效是内源性甲状腺素的3～5倍。口服后吸收良好，蛋白结合率较高，在体内约0.3%以游离形式存在。血中半衰期为1～2日，若甲状腺功能较低时则半衰期会延长；反之，则不到一日。

药动学

T3钠盐胃肠道吸收完全，与T4相比，T3与血浆蛋白的结合程度较低，约0.3%以游离形式存在。在甲状腺功能正常情况下，T3在血中的半衰期约为1～2天；在甲状腺功能减退时略延长，在甲状腺功能亢进时约为0.6天。

适应证

用于需要迅速见效的甲状腺功能减退及黏液性水肿昏迷患者，也可用于甲状腺功能亢进症的诊断。

剂量与用法

• 口服：
  • 成人甲状腺功能减退：初始剂量每日10～25μg，分2～3次服用。每1～2周递增10～25μg，直至甲状腺功能恢复正常；对于年龄大、心功能不全或严重长期甲状腺功能减退的患者，初始剂量要低，增加剂量时幅度要小，加量速度要慢。维持量为每日25～50μg。
  • 诊断成人甲状腺功能亢进症：每日80μg，分3～4次口服，连用7～8日；服药前后进行放射性碘摄取试验，甲状腺功能亢进症者甲状腺对碘的摄取不受抑制，而正常人碘的摄取受到抑制。
• 静脉注射：黏液性水肿昏迷患者初始剂量40～120μg，以后每6小时5～15μg。直至患者清醒时改为口服。

不良反应

1. 甲状腺激素如用量适当无任何不良反应。使用过量则引起心动过速、心悸、心绞痛、心律失常、头痛、神经质、兴奋、不安、失眠、骨路肌痉挛、肌无力、震颤、出汗、潮红、怕热、发热、腹泻、呕吐、体重减轻等类似甲状腺功能亢进的症状。T3过量时，不良反应的发生比T4或甲状腺粉更快,减量或停药可使所有症状消失。T4过量所致者，症状消失较缓慢。
2. 长期大剂量可引起心悸，手震颤，出汗，体重减轻，神经兴奋性升高和失眠。老年和心脏病人可引发心绞痛、心肌梗塞、心源性虚脱，此时应停用本品。

注意事项

1. 不良反应：心血管系统有心悸、心动过速、心绞痛，偶见心律失常与心衰，故冠心病、高血压患者慎用本品；中枢神经系统有头痛、兴奋、失眠、神经质，偶见昏迷；消化系统有恶心、呕吐及腹泻等；其他有肌无力、新陈代谢加快(皮肤潮红、发热、出汗、怕热、体重减轻)，偶见死亡。
2. 本品可会使抗凝剂及三环类抗抑郁药的药效增强。
3. 糖尿病患者服用本品时，应调整好降糖药的剂量，适量增加。
4. 普萘洛尔、胺碘酮可阻止甲状腺素转化成本品，进而导致T3浓度降低与无活性的反T3浓度增高。
5. 若发生急性药物过量时，应立即采取措施，减少药物在胃肠道中的滞留，进而减少机体对药物的吸收，同时还应进行对症治疗和支持治疗。
6. 本品不作为一般替代治疗的首选药。

制剂规格

• 片剂：20μg
• 粉针剂：20μg

参考文献

[1] 刘福强等 主编. 医师案头用药参考. 北京：中国中医药出版社, 2012.

碘塞罗宁钠是一种由原激素甲状腺素（T4）脱碘生成的甲状腺激素，是甲状腺激素受体Trα和Trβ的有效激动剂。

反应信息

• 作为反应物：
  描述：

  liothyronine sodium 在 氯磺酸 、 溶剂黄146 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基乙酰胺 、 水 为溶剂， 反应 6.17h， 生成
  参考文献：
  名称：

  JP5833222

  摘要：

  公开号：
• 作为产物：
  描述：

  3,5-二碘-L-甲状腺素 在 碘 、 乙胺 、 sodium iodide 作用下， 以 水 为溶剂， 反应 7.0h， 生成 liothyronine sodium
  参考文献：
  名称：

  JP5833222

  摘要：

  公开号：

文献信息

• ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF
  申请人：Meng Charles Q.

  公开号：US20140142114A1

  公开（公告）日：2014-05-22

  The present invention relates to novel anthelmintic compounds of formula (I) below: wherein Y and Z are independently a bicyclic carbocyclic or a bicyclic heterocyclic group, or one of Y or Z is a bicyclic carbocyclic or a bicyclic heterocyclic group and the other of Y or Z is alkyl, alkenyl, alkynyl, cycloalkyl, phenyl, heterocyclyl or heteroaryl, and variables X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 and X 8 are as defined herein. The invention also provides for veterinary compositions comprising the anthelmintic compounds of the invention, and their uses for the treatment and prevention of parasitic infections in animals.

  本发明涉及以下式（I）的新型驱虫化合物： 其中 Y和Z分别是双环碳环或双环杂环基团，或者Y或Z中的一个是双环碳环或双环杂环基团，另一个是烷基，烯基，炔基，环烷基，苯基，杂环基或杂芳基，以及变量X 1 ，X 2 ，X 3 ，X 4 ，X 5 ，X 6 ，X 7 和X 8 如本文所定义。本发明还提供了包含本发明的驱虫化合物的兽药组合物，以及它们用于治疗和预防动物寄生虫感染的用途。
• [EN] ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS<br/>[FR] COMPOSÉS DEPSIPEPTIDIQUES ANTHELMINTHIQUES
  申请人：MERIAL INC

  公开号：WO2018093920A1

  公开（公告）日：2018-05-24

  The present invention provides cyclic depsipeptide compounds of formula (I) wherein the stereochemical configuration of at least one carbon atom bearing the groups Cy1, Cy2, R1, R2, R3, R4, Ra and Rb is inverted compared with the naturally occurring cyclic depsipeptide PF1022A. The invention also provides compositions comprising the compounds that are effective against parasites that harm animals. The compounds and compositions may be used for combating parasites in or on mammals and birds. The invention also provides for an improved method for eradicating, controlling and preventing parasite infestation in birds and mammals.

  本发明提供了公式（I）的环状脱氨肽化合物，其中至少一个碳原子的立体化学构型与自然存在的环状脱氨肽PF1022A的基团Cy1、Cy2、R1、R2、R3、R4、Ra和Rb相比发生了倒置。该发明还提供了包含这些化合物的组合物，对危害动物的寄生虫具有有效性。这些化合物和组合物可用于对抗哺乳动物和鸟类体内或体表的寄生虫。该发明还提供了一种改进的方法，用于根除、控制和预防鸟类和哺乳动物的寄生虫感染。
• Benzoxazepinones and their use as squalene synthase inhibitors
  申请人：——

  公开号：US20030078251A1

  公开（公告）日：2003-04-24

  There is disclosed a compound represented by the formula [I]: 1 wherein R 1 is optionally substituted 1-carboxyethyl group, optionally substituted alkyl-sulfonyl group, optionally substituted (carboxy-cycloalkyl)-alkyl group, —X 1 —X 2 —Ar—X 3 —X 4 —COOH (wherein X 1 and X 4 are a bond or alkylene group, X 2 and X 3 are a bond, —O—, —S—, Ar is divalent aromatic group etc.), R 2 is alkyl group optionally substituted with alkanoyloxy group and/or hydroxy group, R 3 is alkyl group, and W is halogen atom, etc., or a salt thereof. The compound has the cholesterol lowering activity and the triglyceride lowering activity and is useful for preventing and/or treating hyperlipidemia.

  披露了一种由公式[I]表示的化合物： 1 其中R 1 是可选地取代的1-羧乙基，可选地取代的烷基亚磺酰基，可选地取代的(羧基环烷基)-烷基，—X 1 —X 2 —Ar—X 3 —X 4 —COOH(其中X 1 和X 4 是键或亚烷基，X 2 和X 3 是键，—O—，—S—，Ar是二价芳香族等)，R 2 是可选地由酰氧基和/或羟基取代的烷基，R 3 是烷基，W是卤素原子等，或其盐。该化合物具有降低胆固醇活性和降低甘油三酯活性，用于预防或治疗高脂血症。
• BENZAZEPINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1422228A1

  公开（公告）日：2004-05-26

  The present invention provides a novel benzazepine derivative represented by formula : wherein, R1 is a 5- or 6-membered aromatic ring, R2 is lower alkyl group, etc., Y is an optionally substituted imino group, ring A and ring B are independently an optionally substituted aromatic ring, W is formula -W1-X2-W2- (W1 and W2 are independently S(O)m1 (m1 is 0, 1 or 2), etc., and X2 is an optionally substituted alkylene groupetc. ), a preparation method and use thereof.

  本发明提供了一种新型的苯并氮杂环衍生物，其由以下公式表示： 其中，R1是一个5-或6-成员的芳香环，R2是低级烷基团等，Y是可选地取代的亚氨基，环A和环B是独立地选自一个可选地取代的芳香环，W是公式-W1-X2-W2-（W1和W2是独立地为S(O)m1（m1是0、1或2）等，X2是一个可选地取代的亚烷基团等），其制备方法及其用途。
• [EN] ANTI PARASITIC DIHYDROAZOLE COMPOUNDS AND COMPOSITIONS COMPRISING SAME<br/>[FR] DIHYDROAZOLES ANTIPARASITAIRES ET COMPOSITIONS LES INCLUANT
  申请人：MERIAL LTD

  公开号：WO2011075591A1

  公开（公告）日：2011-06-23

  The present invention relates to novel dihydroazole of formula (I) and salts thereof: Wherein R1, A1, A2, G, X and Y are as defined in the description, compositions thereof, processes for their preparation and their uses to prevent or treat parasitic infections or infestations in animals and as pesticides.

  本发明涉及式(I)的新型二氢咪唑及其盐：其中R1、A1、A2、G、X和Y如描述中所定义，以及它们的组合物、制备方法以及它们用于预防或治疗动物寄生虫感染或寄生虫侵袭以及作为杀虫剂的用途。

表征谱图